Artificial Intelligence & Machine Learning , Big Data Security Analytics , Fraud Management & Cybercrime

Fighting Drug Diversion Fraud With Technology

Pfizer’s Charles Washington on the Roles of Analytics, AI
Charles Washington, senior director, global fraud and asset protection, Pfizer

Pharmaceutical companies can leverage data analytics, predictive analytics and artificial intelligence to fight drug diversion fraud, says Charles Washington, senior director, global fraud and asset protection, at Pfizer.

See Also: OnDemand | Payments Without Borders: Prevent Fraud and Improve the Customer Experience

Drug diversion fraud involves the transfer of any legally prescribed controlled substance from the individual for whom it was prescribed to another person for any illicit use.

“Most companies have systems that are well built to keep unwanted external data from coming into the company," Washington says. "They also have strong systems to keep confidential data inside the system. But when it comes to diversion data, it is hidden within all of this legitimate sales data that flows into the company from the outside."

In a video interview with Information Security Media Group, Washington also discusses:

  • The various aspects of drug diversion fraud;
  • How the pharmaceutical industry is responding to such fraud;
  • Challenges in leveraging technologies to deal with drug diversion fraud.

Washington is a senior director, global fraud and asset protection at the pharmaceutical company Pfizer. He is responsible for external fraud prevention, investigation and recovery strategies. He developed one of the first global programs in the pharmaceutical industry dedicated to fighting fraud.


About the Author

Suparna Goswami

Suparna Goswami

Associate Editor, ISMG

Goswami has more than 10 years of experience in the field of journalism. She has covered a variety of beats including global macro economy, fintech, startups and other business trends. Before joining ISMG, she contributed for Forbes Asia, where she wrote about the Indian startup ecosystem. She has also worked with UK-based International Finance Magazine and leading Indian newspapers, such as DNA and Times of India.




Around the Network

Our website uses cookies. Cookies enable us to provide the best experience possible and help us understand how visitors use our website. By browsing inforisktoday.co.uk, you agree to our use of cookies.